Multiple Myeloma Essay

1211 Words 5 Pages
Multiple myeloma is a form of cancer that is caused by the formation of abnormal plasma cells, which become malignant. Plasma cells arise from B lymphocytes that are formed in the bone marrow; specifically the lymph nodes and spleen. When a foreign particle enters the body the immune system triggers an immune response which triggers B cells to produce plasma cells. The plasma cells make immunoglobulins. Immunoglobulins are antibodies that attaches themself to the target antigen in order for neutralization or destruction to occur, which will prevent the risk of an infection or disease. When the plasma cells become malignant, they chaotically increase and produce tumors called plasmacytoma. Plasmacytoma are solid masses of neoplastic monoclonal …show more content…
Myeloma cells produce antibodies called monoclonal protein, which build up in the blood and urine. A buildup of monoclonal protein the blood and urine, may damage the kidneys and organs. Myeloma regularly causes bone damage such as painful fractures or bone breakage. This type of cancer is the fourteenth leading cause of cancer deaths and it is the third most common blood based cancer in the United States. The American Cancer Society predicts that there will be an estimate of 30,330 new cases of those diagnosed with multiple myeloma this year and approximately 12,650 deaths. There are various treatments offered to myeloma patients such as chemotherapy, other drug therapy, stem cell transplant, bone marrow transplant, radiation therapy, and surgery. These treatments may not cure myeloma patients; however, the FDA recently discovered and approved a new drug on November 16th, 2015 of that has the potential to help find the cure for Multiple Myeloma because it is a form of target therapy. This drug is called …show more content…
These trials consisted of 106 people afflicted with multiple myeloma. They had to have received at least 3 prior treatments, a primary immunodeficiency (PI), and an immunomodulatory agent. When the patient had received both the PI and the immunomodulatory agent, they were observed to make sure that the their condition had not deteriorated significantly and if it has then the patient must receive a median of 5 prior treatments. The Darzalex was given as a monotherapy. In other words, it was given alone and during the test trials was not combined with any other multiple myeloma

Related Documents